Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [14896]

EHA 2022: Magrolimab and azacitidine show durable responses and encouraging results in TP53-mutant AML

EHA 2022: Magrolimab and azacitidine show durable responses and encouraging results in TP53-mutant AML

EHA 2022: Targeted therapy emavusertib shows encouraging activity in MDS and AML with specific mutations

EHA 2022: Targeted therapy emavusertib shows encouraging activity in MDS and AML with specific mutations

EHA 2022: Ponatinib and blinatumomab combination has high response rates for patients with PH+ ALL

EHA 2022: Ponatinib and blinatumomab combination has high response rates for patients with PH+ ALL

EHA 2022: Ibrutinib combination with bendamustine-rituximab and rituximab maintenance as a first-line treatment for older patients with mantle cell lymphoma significantly improves PFS

EHA 2022: Ibrutinib combination with bendamustine-rituximab and rituximab maintenance as a first-line treatment...

EHA 2022: Transforming transfusion-dependent β-thalassemia and sickle cell disease with a single CRISPR/Cas9 gene-edited therapy

EHA 2022: Transforming transfusion-dependent β-thalassemia and sickle cell disease with a single CRISPR/Cas9 gene...

$EHA 2022: A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma$

EHA 2022: A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory...

EHA 2022: Improved progression-free survival is achievable using targeted therapy combinations with venetoclax in fit patients with treatment-naïve chronic lymphocytic leukaemia

EHA 2022: Improved progression-free survival is achievable using targeted therapy combinations with venetoclax in...

Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy

Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy

ASCO 2022: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy

ASCO 2022: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid...

Bridge therapy may benefit some children with high-risk neuroblastoma

Bridge therapy may benefit some children with high-risk neuroblastoma

More from ecancer